Table 2.
Number of repeat injections.
| Study | Number of injections |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| Kuschel et al. [2008] | 26 | 11 | 1 | – | – | – | – | – | – | – |
| Khan et al. [2009] | 81 | 24 | 13 | 6 | 4 | 1 | – | – | – | – |
| Sahai et al. [2010] | 34 | 20 | 9 | 9 | – | – | – | – | – | – |
| Frohme et al. [2010] (in German) | 40 | 15 | 4 | 1 | – | – | – | – | – | – |
| Game et al. [2011] | 42 | 42 | 16 | 12 | 10 | – | – | – | – | – |
| Gousse et al. [2011] | 60 | 36 | 23 | 16 | 12 | 9 | – | – | – | – |
| Dowson et al. [2012] | 100 | 53 | 20 | 13 | 10 | 5 | 3 | 1 | 1 | 1 |
| Granese et al. [2012] | 68 | 20 | – | – | – | – | – | – | – | – |
| Veeratterapillay et al. [2014] * $ | – | 125 | 60 | 28 | 14 | 3 | 3 | 2 | – | – |
| Nitti et al. [2016] | 829 | 608 | 388 | 273 | 185 | 139 | – | – | – | – |
*
Includes patients with idiopathic detrusor overactivity and NDO.
$
All patients received repeat injections.
NDO, neurogenic detrusor overactivity; NR, not reported.